CLN-617 retains IL-2 and IL-12 in injected tumors to drive robust and systemic immune-mediated antitumor activity
# 10X RBC Lysis Buffer ; # 64010-00 ; Cancer Immunol Res. 2024 Jun 6. doi: 10.1158/2326-6066.CIR-23-0636. Online ahead of print. Naveen K Mehta 1, Kavya Rakhra 1, Kristan A Meetze 1, Bochong Li 1, Noor Momin 2, Jason Yh Chang 1, K Dane Wittrup 3, Patrick A Baeuerle 4, Jennifer S Michaelson 1 Affiliations expand Abstract Despite clinical evidence of antitumor activity, the development of cytokine therapies has been hampered by a …